A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
Status:
Completed
Trial end date:
2015-04-01
Target enrollment:
Participant gender:
Summary
A study examining the safety of AGS-22M6E or ASG-22CE administered as monotherapy therapy in
subjects with malignant solid tumors that express Nectin-4.